The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Why would you want to be taken over by a big pharmaceutical company?
This is new emerging medication basically hasnt even learned to crawl yet when it starts to walk in a few years its a win win for us all. Mgc should resist any takeover.
Whats the probability...I wonder. For example how many small pharmas get taken over each year. Versus how many small pharmas exist. Anyone got any figures?
Affinivax's estimated annual revenue is currently $39.9M per year, taken over by GSK for $3.2 billion. We need something similar here.
Nice one Mornington, positivity hopefully will prevail.
Last message meant for Fazer, sorry :)
Gazzle, yes sometimes luck and timing play an important part.
$3 billion, what was Affinivax mkt cap prior to the takeover. I’m not sure how you’d put a figure on our company worth/potential.
Lots got stung with Nova Mornington, glad I pulled out with a small gain
One piece of news is all it takes, NCYT went from around 6p to nearly £13 in a matter of months.
Sadly I sold out of there far to early but never envisaged it going as high as it did.
Just going to flat line today , the couple of weeks we might hit the skys but I won’t hold my breath
I suppose the potential is massive and this isn’t AIM so hopefully less risky but who knows, one piece of news could be a game changer. I’d like to see us close to the target price of 7.20 for starters.
How high do you think price will go if there is an early takeover. I personally doubt there will be as its still early days with clinical trials etc..
A great buying opportunity at the current price, I’m hoping this will be back to 5p+ over the coming months.
Blimey, a sea of blue and on the top risers here.
Stew, at what price do you think we’d be bought out at? Our current mkt cap is 30M
We won't
This will get snapped up soon